News
AZRX
--
0.00%
--
BioMedNewsBreaks - AzurRx BioPharma Inc. (NASDAQ: AZRX) Shareholder Letter Outlines Program Highlights, Provides Business Update
Apr 15, 2021 (Investor Brand Network via COMTEX) -- AzurRx BioPharma (NASDAQ: AZRX), a clinical stage biopharmaceutical company specializing in the...
Investor Brand Network · 1d ago
AzurRx BioPharma CEO Issues Letter To Shareholders
AzurRx BioPharma, Inc. (NASDAQ:AZRX), ("AzurRx" or the "Company"), a clinical stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies
Benzinga · 1d ago
AzurRx BioPharma (AZRX) Receives a Buy from H.C. Wainwright
H.C. Wainwright analyst Yi Chen reiterated a Buy rating on AzurRx BioPharma (AZRX) today and set a price target of $2.50. The company's shares closed last
SmarterAnalyst · 2d ago
BioMedNewsBreaks - AzurRx BioPharma Inc. (NASDAQ: AZRX) Enters Agreement for Upcoming Phase 1b/2a Clinical Trial
Apr 13, 2021 (Investor Brand Network via COMTEX) -- AzurRx BioPharma (NASDAQ: AZRX), a clinical stage biopharmaceutical company specializing in the...
Investor Brand Network · 3d ago
AzurRx Biopharma engages PPD to manage niclosamide clinical trial
AzurRx BioPharma ([[AZRX]] -7.8%) has entered into an agreement with global contract research organization PPD > for its planned Phase 1b/2a clinical trial evaluating proprietary formulations of micronized niclosamide for grade 1 colitis
Seekingalpha · 3d ago
AzurRx BioPharma Says Engages PPD To Manage Clinical Trial For Niclosamide As Treatment For Grade 1 Immune Checkpoint Inhibitor-Associated Colitis
AzurRx BioPharma, Inc. (NASDAQ:AZRX), ("AzurRx" or the "Company"), a clinical stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies
Benzinga · 3d ago
Nonhospitalized Long-Haul Coronavirus Patients Susceptible to Cognitive Dysfunction
Apr 12, 2021 (Investor Brand Network via COMTEX) -- A group of researchers from the Feinberg School of Medicine at Northwestern University has discovered...
Investor Brand Network · 4d ago
Exocrine Pancreatic Insufficiency Market Size ,Share 2021: Global Sales Revenue, Emerging Technologies, Growth Status, Key Players Analysis, Development Status, Opportunity Assessment and Industry Expansion Strategies 2025
Apr 12, 2021 (The Expresswire) -- Global Exocrine Pancreatic Insufficiency Market Research report provides detailed analysis of global market size, regional...
The Express Wire · 4d ago
AzurRx BioPharma (AZRX) Received its Third Buy in a Row
After Roth Capital and Maxim Group gave AzurRx BioPharma (NASDAQ: AZRX) a Buy rating last month, the company received another Buy, this time from H.C.
SmarterAnalyst · 04/07 10:16
BioMedNewsBreaks - AzurRx BioPharma Inc. (NASDAQ: AZRX) Initiates Phase 2 RESERVOIR Trial for Treatment of COVID-19 GI Infections
Apr 06, 2021 (Investor Brand Network via COMTEX) -- AzurRx BioPharma (NASDAQ: AZRX), a clinical stage biopharmaceutical company specializing in the...
Investor Brand Network · 04/06 15:03
AzurRx BioPharma To Test Formulated Niclosamide In COVID-19-Related Gastrointestinal Infections
Benzinga · 04/06 14:41
BRIEF-AzurRx Biopharma Initiates Phase 2 Clinical Trial Of Niclosamide For Treatment Of Covid-19 Gastrointestinal Infections
reuters.com · 04/06 11:12
AzurRx BioPharma Initiates Phase 2 Clinical Trial of Niclosamide for the Treatment of COVID-19 Gastrointestinal Infections
“RESERVOIR” trial to evaluate niclosamide’s ability to target SARS-CoV-2 in the GI tract Topline data expected in Q1 2022 DELRAY BEACH, Fla., April 06, 2021 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (NASDAQ: AZRX), (“AzurRx” or the “Company”), a clinical ...
GlobeNewswire · 04/06 11:00
Mid-Afternoon Market Update: Nasdaq Jumps Over 200 Points; AzurRx BioPharma Shares Slide
Toward the end of trading Thursday, the Dow traded up 0.49% to 33,143.12 while the NASDAQ rose 1.56% to 13,454.06. The S&P also rose, gaining 0.97% to 4,011.57.
Benzinga · 04/01 18:37
8-K: AzurRx BioPharma, Inc.
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act...
Edgar Online - (EDK = 8-Ks/S1/S-4) · 04/01 16:42
NVVE, UXIN, MVIS and XSPA among midday movers
Gainers: AeroCentury (ACY) +235%.Liberty TripAdvisor (LTRPB) +106%.Uxin (UXIN) +53%.Universe Pharmaceuticals (UPC) +36%.Applied Molecular Transport (AMTI) +31%.Euro Tech Holdings (CLWT) +26%.PLBY Group (PLBY) +25%.Nuvve (NVVE) +24%.Moxian (MOXC) +18%.Sonom...
Seekingalpha · 04/01 16:42
BioMedNewsBreaks - AzurRx BioPharma Inc. (NASDAQ: AZRX) Announces Key Results from Phase 2b OPTION 2 Clinical Trial
Apr 01, 2021 (Investor Brand Network via COMTEX) -- AzurRx BioPharma (NASDAQ: AZRX), a clinical stage biopharmaceutical company specializing in the...
Investor Brand Network · 04/01 16:27
Mid-Day Market Update: Crude Oil Rises Over 1%; BioXcel Therapeutics Shares Plummet
Midway through trading Thursday, the Dow traded up 0.25% to 33,064.19 while the NASDAQ rose 1.71% to 13,473.41. The S&P also rose, gaining 0.84% to 4,006.35.
Benzinga · 04/01 16:04
Webull provides a variety of real-time AZRX stock news. You can receive the latest news about AzurRx through multiple platforms. This information may help you make smarter investment decisions.
About AZRX
AzurRx BioPharma, Inc. is a clinical development-stage biopharmaceutical company. The Company is engaged in the research and development of non-systemic biologics for the treatment of patients with gastrointestinal (GI) disorders. The Company's product pipeline consists of two therapeutic proteins, such as MS1819 and AZX1101. MS1819 is an acid-resistant secreted lipase produced by Yarrowia lipolytica, known as LIP2, that the Company is developing through recombinant deoxyribonucleic acid (DNA) technology for the treatment of exocrine pancreatic insufficiency (EPI), associated with chronic pancreatitis (CP) and cystic fibrosis (CF). AZX1101 is a recombinant-lactamase combination of bacterial origin under development for the prevention of hospital-acquired infections by resistant bacterial strains induced by parenteral administration of b-lactam antibiotics (known as nosocomial infections), as well as the prevention of antibiotic-associated diarrhea (AAD).